Articles

Pharmaceutical Technology® spoke with Todd Sprouse, associate director, Analytical Services, and Erik Feldmann, PhD, principal technical advisor, Client Solutions & Proposals, both with Cambrex, to find out more about the challenging situation.  

The Continuous Challenge of Nitrosamines

Feliza Mirasol is the science editor for 

Videos

Dan Williams, CEO of SynaptixBio emphasizes how small biotechs are using genetic research and partnerships to accelerate rare disease innovation in the final installment of his interview.

The Role of Genetic Advances and Partnerships in Rare Disease Drug Development (Part 3)

The Phase IIa study will test HTL0039732 in combination with immunotherapy to boost responses in resistant solid tumors and broaden treatment choices.

Cancer Research UK Partners with Nxera on Next-Stage Trial for HTL0039732 

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The company has expanded its CDMO offerings in recent years, adding to decades of experiences in solutions such as moisture management.

Sanner Previews CPHI Frankfurt Portfolio of CDMO Services, Packaging Innovations

Misleading promotions of GLP-1 and compounded semaglutide products are drawing renewed regulatory scrutiny over risk disclosure and safety messaging.

Lilly, Novo, Hims Get FDA Warnings About Misleading Drug Communications

Corstasis Therapeutics plans to launch the product in the United States in the fourth quarter of 2025.

FDA Approves Cortasis Nasal Spray, Enbumyst, for Edema

Cheryl Barton is director of PharmaVision, 

Novo Nordisk’s Wegovy will be competing with Madrigal Pharmaceuticals’ Rezdiffra in the metabolic dysfunction-associated steatohepatitis arena. 

Competition in MASH is Heating Up as GLP-1s Gate-Crash the Party

UK pharma small- and medium-sized enterprises face funding and R&D barriers. Improved tax relief and targeted incentives are vital to keep UK innovation competitive.

Op/Ed: Rethinking R&D Tax Relief–Why Smarter Incentives Are Key to Unlocking UK Pharma Innovation

The 2024 edition of the annual conference, held in Milan, attracted more than 59,000 professionals from across the bio/pharmaceutical landscape.

CPHI Frankfurt Expected to Draw More Than 60,000 Attendees in October

This potential shift has profound implications for regulatory strategy, transparency, and internal quality systems, directly impacting the core concerns of industry professionals.

News